Markets:

Overview

News

Currencies

International

Treasuries

Matinas Biopharma Holdings, Inc. Common Stock (NY:MTNB)

0.2930 -0.0370 (-11.21%)

Official Closing Price Updated: 8:00 PM EDT, Jul 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Matinas Biopharma Holdings, Inc. Common Stock

< Previous 1 2 3 4 5 Next >

Earnings Scheduled For March 15, 2023 ↗

March 15, 2023

Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.

Via Benzinga

Earnings Outlook For Matinas BioPharma Hldgs ↗

March 14, 2023

Via Benzinga

Matinas BioPharma: Q2 Earnings Insights ↗

August 11, 2022

Matinas BioPharma Hldgs (AMEX:MTNB) reported its Q2 earnings results on Thursday, August 11, 2022 at 06:15 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For August 11, 2022 ↗

August 11, 2022

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

March 14, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 09, 2023

Via Benzinga

Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday ↗

October 24, 2022

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.

Via Benzinga

Matinas BioPharma Hldgs: Q1 Earnings Insights ↗

May 12, 2022

Matinas BioPharma Hldgs (AMEX:MTNB) reported its Q1 earnings results on Thursday, May 12, 2022 at 06:15 AM. Here's what investors need to know about the announcement.

Via Benzinga

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More ↗

May 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

A Preview Of Matinas BioPharma Hldgs's Earnings ↗

May 11, 2022

Matinas BioPharma Hldgs (AMEX:MTNB) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

HC Wainwright Reiterates Buy Rating On BioNTech, While Lowers Price Target ↗

April 12, 2022

HC Wainwright has reiterated its Buy rating on BioNTech SE (NASDAQ: BNTX) while reducing the price tar

Via Benzinga

BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines ↗

April 11, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech ↗

April 11, 2022

BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have

Via Benzinga

Here's Why Matinas BioPharma Shares Are Rising ↗

April 11, 2022

Matinas BioPharma Holdings Inc (NASDAQ: MTNB) shares are trading higher by 10.4% at $0.86 after the company and BioNTech announced an exclusive research collaboration to...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

March 25, 2022

Good morning, trader! Get ready for one more busy day of investing today with the biggest pre-market stock movers for Friday!

Via InvestorPlace

34 Stocks Moving in Friday's Pre-Market Session ↗

March 25, 2022

Gainers Clever Leaves Holdings Inc. (NASDAQ: CLVR) rose 40.5% to $2.22 in pre-market trading after the company reported better-than-expected Q4 sales results and reaffirmed FY22...

Via Benzinga

Matinas BioPharma Updates — Q4 2021 Earnings And Conference Call Recap ↗

March 21, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout ↗

March 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative...

Via Benzinga

Matinas BioPharma: Q4 Earnings Insights ↗

March 08, 2022

Matinas BioPharma Hldgs (AMEX:MTNB) reported its Q4 earnings results on Tuesday, March 8, 2022 at 06:15 AM. Here's what investors need to know about the announcement....

Via Benzinga

Earnings Scheduled For March 8, 2022 ↗

March 08, 2022

Companies Reporting Before The Bell • Babcock & Wilcox (NYSE:BW) is likely to report quarterly earnings at $0.10 per share on revenue of $196.62 million. •...

Via Benzinga

Earnings Preview For Matinas BioPharma Hldgs ↗

March 07, 2022

Matinas BioPharma Hldgs (AMEX:MTNB) is set to give its latest quarterly earnings report on Tuesday, 2022-03-08. Here's what investors need to know before the announcement....

Via Benzinga

The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗

March 06, 2022

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

December 08, 2021

We've reached the halfway point of the week and there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

51 Biggest Movers From Yesterday ↗

January 26, 2022

Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares climbed 46.2% to close at $22.68 on Tuesday after the company unveiled topline data for momelotinib in myelofibrosis patients...

Via Benzinga

22 Stocks Moving in Wednesday's Pre-Market Session ↗

December 08, 2021

Gainers Daré Bioscience, Inc. (NASDAQ: DARE) rose 45.2% to $3.08 in pre-market trading after the company reported the FDA approval of XACIATO Vaginal Gel as a treatment...

Via Benzinga

Is Next-Generation Drug Delivery Coming to a Hospital Near You? ↗

December 01, 2021

Photo by Anna Shvets on Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner...

Via Benzinga

On Target: This Company Says It Delivers Drugs Exactly How You Need Them ↗

November 15, 2021

Photo by Anna Shvets from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

46 Biggest Movers From Yesterday ↗

October 12, 2021

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full clinical hold on Protagonist Therapeutics’...

Via Benzinga

Earnings Scheduled For November 8, 2021 ↗

November 08, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...

Via Benzinga

28 Stocks Moving In Monday's Mid-Day Session ↗

October 11, 2021

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on Protagonist Therapeutics’ rusfertide clinical...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.